The management of pyothorax-associated lymphoma using 18F-FDG PET/CT
Objective Pyothorax-associated lymphoma (PAL) is a rare form of lymphoma and its management on 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined computed tomography (CT) has not been well reported. The purpose of this study was to evaluate the usefulness of FDG PET/CT in pati...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2010-11, Vol.24 (9), p.649-654 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 654 |
|---|---|
| container_issue | 9 |
| container_start_page | 649 |
| container_title | Annals of nuclear medicine |
| container_volume | 24 |
| creator | Ito, Kimiteru Shida, Yoshitaka Kubota, Kazuo Morooka, Miyako Aruga, Takashi Itami, Jun Matsuda, Hiroshi |
| description | Objective
Pyothorax-associated lymphoma (PAL) is a rare form of lymphoma and its management on
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined computed tomography (CT) has not been well reported. The purpose of this study was to evaluate the usefulness of FDG PET/CT in patients with PAL.
Materials and methods
Twenty-four PET/CT images in seven patients (5 men and 2 women) with PAL were studied retrospectively. Five of the 24 PET/CT scans were done for diagnosis and staging, 6 for restaging, 3 for follow-up, and 10 to evaluate the treatment response. PET/CT scan interpretations were performed visually and using the maximum standardized uptake values (SUVmax). Additionally, the efficacy of the enhanced CT findings in pre- and post-treatments was described.
Results
Six of the 7 patients with PAL received radiotherapy, and the efficacy of treatment was observed in their lesions. The percentage decrease of SUVmax in PAL was useful in providing complementary information. Enhanced CT findings showed decreasing enhancement of PAL after treatment; however, in five cases, residual masses were confirmed after treatment.
Conclusion
FDG PET/CT may be an ideal modality for reducing the false-positive interpretation of residual masses occurring after treatment for PAL. The SUVmax provides complementary information for the management of PAL. |
| doi_str_mv | 10.1007/s12149-010-0408-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_808466084</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>808466084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3054-5b05a8dfff9f163e082cde0a331cdd0dba58f14722e02b22e1b539fc55a0375a3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBdZvHiKnXxt0qP0S6Ggh_UcsrtJP-hu6qYL9t-bslVB8DJzmGfeGR6Ebgk8EgA5DIQSPsJAAAMHhfkZ6hOVcpxyxs5RH0aEY0mU7KGrEDYAVAlFL1GPguTAGPTRJFvZpDK1WdrK1vvEu2R38PuVb8wnNiH4Ym32tky2h2q38pVJ2rCulwlRMzybzJO3aTYcZ9fowpltsDenPkDvs2k2fsaL1_nL-GmBCwaCY5GDMKp0zo0cSZkFRYvSgmGMFGUJZW6EcoRLSi3QPFaSCzZyhRAGmBSGDdBDl7tr_Edrw15X61DY7dbU1rdBK1A8TWOJ5P0fcuPbpo7PRUgKmaapjBDpoKLxITTW6V2zrkxz0AT0UbDuBOsoWB8F62Pw3Sm4zStb_mx8G40A7YAQR_XSNr-X_0_9Al8Vg04</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>807576667</pqid></control><display><type>article</type><title>The management of pyothorax-associated lymphoma using 18F-FDG PET/CT</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Ito, Kimiteru ; Shida, Yoshitaka ; Kubota, Kazuo ; Morooka, Miyako ; Aruga, Takashi ; Itami, Jun ; Matsuda, Hiroshi</creator><creatorcontrib>Ito, Kimiteru ; Shida, Yoshitaka ; Kubota, Kazuo ; Morooka, Miyako ; Aruga, Takashi ; Itami, Jun ; Matsuda, Hiroshi</creatorcontrib><description>Objective
Pyothorax-associated lymphoma (PAL) is a rare form of lymphoma and its management on
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined computed tomography (CT) has not been well reported. The purpose of this study was to evaluate the usefulness of FDG PET/CT in patients with PAL.
Materials and methods
Twenty-four PET/CT images in seven patients (5 men and 2 women) with PAL were studied retrospectively. Five of the 24 PET/CT scans were done for diagnosis and staging, 6 for restaging, 3 for follow-up, and 10 to evaluate the treatment response. PET/CT scan interpretations were performed visually and using the maximum standardized uptake values (SUVmax). Additionally, the efficacy of the enhanced CT findings in pre- and post-treatments was described.
Results
Six of the 7 patients with PAL received radiotherapy, and the efficacy of treatment was observed in their lesions. The percentage decrease of SUVmax in PAL was useful in providing complementary information. Enhanced CT findings showed decreasing enhancement of PAL after treatment; however, in five cases, residual masses were confirmed after treatment.
Conclusion
FDG PET/CT may be an ideal modality for reducing the false-positive interpretation of residual masses occurring after treatment for PAL. The SUVmax provides complementary information for the management of PAL.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-010-0408-4</identifier><identifier>PMID: 20740330</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Aged ; Aged, 80 and over ; Biological Transport ; Empyema, Pleural - complications ; Female ; Fluorodeoxyglucose F18 - metabolism ; Follow-Up Studies ; Humans ; Imaging ; Lymphoma - complications ; Lymphoma - diagnosis ; Lymphoma - pathology ; Lymphoma - therapy ; Male ; Medicine ; Medicine & Public Health ; Neoplasm Staging ; Nuclear Medicine ; Original Article ; Positron-Emission Tomography ; Radiology ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Annals of nuclear medicine, 2010-11, Vol.24 (9), p.649-654</ispartof><rights>The Japanese Society of Nuclear Medicine 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3054-5b05a8dfff9f163e082cde0a331cdd0dba58f14722e02b22e1b539fc55a0375a3</citedby><cites>FETCH-LOGICAL-c3054-5b05a8dfff9f163e082cde0a331cdd0dba58f14722e02b22e1b539fc55a0375a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-010-0408-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-010-0408-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20740330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Kimiteru</creatorcontrib><creatorcontrib>Shida, Yoshitaka</creatorcontrib><creatorcontrib>Kubota, Kazuo</creatorcontrib><creatorcontrib>Morooka, Miyako</creatorcontrib><creatorcontrib>Aruga, Takashi</creatorcontrib><creatorcontrib>Itami, Jun</creatorcontrib><creatorcontrib>Matsuda, Hiroshi</creatorcontrib><title>The management of pyothorax-associated lymphoma using 18F-FDG PET/CT</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><addtitle>Ann Nucl Med</addtitle><description>Objective
Pyothorax-associated lymphoma (PAL) is a rare form of lymphoma and its management on
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined computed tomography (CT) has not been well reported. The purpose of this study was to evaluate the usefulness of FDG PET/CT in patients with PAL.
Materials and methods
Twenty-four PET/CT images in seven patients (5 men and 2 women) with PAL were studied retrospectively. Five of the 24 PET/CT scans were done for diagnosis and staging, 6 for restaging, 3 for follow-up, and 10 to evaluate the treatment response. PET/CT scan interpretations were performed visually and using the maximum standardized uptake values (SUVmax). Additionally, the efficacy of the enhanced CT findings in pre- and post-treatments was described.
Results
Six of the 7 patients with PAL received radiotherapy, and the efficacy of treatment was observed in their lesions. The percentage decrease of SUVmax in PAL was useful in providing complementary information. Enhanced CT findings showed decreasing enhancement of PAL after treatment; however, in five cases, residual masses were confirmed after treatment.
Conclusion
FDG PET/CT may be an ideal modality for reducing the false-positive interpretation of residual masses occurring after treatment for PAL. The SUVmax provides complementary information for the management of PAL.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological Transport</subject><subject>Empyema, Pleural - complications</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - metabolism</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Imaging</subject><subject>Lymphoma - complications</subject><subject>Lymphoma - diagnosis</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Staging</subject><subject>Nuclear Medicine</subject><subject>Original Article</subject><subject>Positron-Emission Tomography</subject><subject>Radiology</subject><subject>Retrospective Studies</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBdZvHiKnXxt0qP0S6Ggh_UcsrtJP-hu6qYL9t-bslVB8DJzmGfeGR6Ebgk8EgA5DIQSPsJAAAMHhfkZ6hOVcpxyxs5RH0aEY0mU7KGrEDYAVAlFL1GPguTAGPTRJFvZpDK1WdrK1vvEu2R38PuVb8wnNiH4Ym32tky2h2q38pVJ2rCulwlRMzybzJO3aTYcZ9fowpltsDenPkDvs2k2fsaL1_nL-GmBCwaCY5GDMKp0zo0cSZkFRYvSgmGMFGUJZW6EcoRLSi3QPFaSCzZyhRAGmBSGDdBDl7tr_Edrw15X61DY7dbU1rdBK1A8TWOJ5P0fcuPbpo7PRUgKmaapjBDpoKLxITTW6V2zrkxz0AT0UbDuBOsoWB8F62Pw3Sm4zStb_mx8G40A7YAQR_XSNr-X_0_9Al8Vg04</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Ito, Kimiteru</creator><creator>Shida, Yoshitaka</creator><creator>Kubota, Kazuo</creator><creator>Morooka, Miyako</creator><creator>Aruga, Takashi</creator><creator>Itami, Jun</creator><creator>Matsuda, Hiroshi</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201011</creationdate><title>The management of pyothorax-associated lymphoma using 18F-FDG PET/CT</title><author>Ito, Kimiteru ; Shida, Yoshitaka ; Kubota, Kazuo ; Morooka, Miyako ; Aruga, Takashi ; Itami, Jun ; Matsuda, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3054-5b05a8dfff9f163e082cde0a331cdd0dba58f14722e02b22e1b539fc55a0375a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological Transport</topic><topic>Empyema, Pleural - complications</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - metabolism</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Imaging</topic><topic>Lymphoma - complications</topic><topic>Lymphoma - diagnosis</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Staging</topic><topic>Nuclear Medicine</topic><topic>Original Article</topic><topic>Positron-Emission Tomography</topic><topic>Radiology</topic><topic>Retrospective Studies</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Kimiteru</creatorcontrib><creatorcontrib>Shida, Yoshitaka</creatorcontrib><creatorcontrib>Kubota, Kazuo</creatorcontrib><creatorcontrib>Morooka, Miyako</creatorcontrib><creatorcontrib>Aruga, Takashi</creatorcontrib><creatorcontrib>Itami, Jun</creatorcontrib><creatorcontrib>Matsuda, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Kimiteru</au><au>Shida, Yoshitaka</au><au>Kubota, Kazuo</au><au>Morooka, Miyako</au><au>Aruga, Takashi</au><au>Itami, Jun</au><au>Matsuda, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The management of pyothorax-associated lymphoma using 18F-FDG PET/CT</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><addtitle>Ann Nucl Med</addtitle><date>2010-11</date><risdate>2010</risdate><volume>24</volume><issue>9</issue><spage>649</spage><epage>654</epage><pages>649-654</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Objective
Pyothorax-associated lymphoma (PAL) is a rare form of lymphoma and its management on
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined computed tomography (CT) has not been well reported. The purpose of this study was to evaluate the usefulness of FDG PET/CT in patients with PAL.
Materials and methods
Twenty-four PET/CT images in seven patients (5 men and 2 women) with PAL were studied retrospectively. Five of the 24 PET/CT scans were done for diagnosis and staging, 6 for restaging, 3 for follow-up, and 10 to evaluate the treatment response. PET/CT scan interpretations were performed visually and using the maximum standardized uptake values (SUVmax). Additionally, the efficacy of the enhanced CT findings in pre- and post-treatments was described.
Results
Six of the 7 patients with PAL received radiotherapy, and the efficacy of treatment was observed in their lesions. The percentage decrease of SUVmax in PAL was useful in providing complementary information. Enhanced CT findings showed decreasing enhancement of PAL after treatment; however, in five cases, residual masses were confirmed after treatment.
Conclusion
FDG PET/CT may be an ideal modality for reducing the false-positive interpretation of residual masses occurring after treatment for PAL. The SUVmax provides complementary information for the management of PAL.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>20740330</pmid><doi>10.1007/s12149-010-0408-4</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2010-11, Vol.24 (9), p.649-654 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_808466084 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Aged, 80 and over Biological Transport Empyema, Pleural - complications Female Fluorodeoxyglucose F18 - metabolism Follow-Up Studies Humans Imaging Lymphoma - complications Lymphoma - diagnosis Lymphoma - pathology Lymphoma - therapy Male Medicine Medicine & Public Health Neoplasm Staging Nuclear Medicine Original Article Positron-Emission Tomography Radiology Retrospective Studies Tomography, X-Ray Computed Treatment Outcome |
| title | The management of pyothorax-associated lymphoma using 18F-FDG PET/CT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A20%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20management%20of%20pyothorax-associated%20lymphoma%20using%2018F-FDG%20PET/CT&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Ito,%20Kimiteru&rft.date=2010-11&rft.volume=24&rft.issue=9&rft.spage=649&rft.epage=654&rft.pages=649-654&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-010-0408-4&rft_dat=%3Cproquest_cross%3E808466084%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=807576667&rft_id=info:pmid/20740330&rfr_iscdi=true |